EGFR and head and neck squamous cell carcinoma: ,4,5,6,7 Subgroup analyses from pivotal anti-PD1 trials have indicated that HNSCC patients previously treated with the anti-EGFR antibody cetuximab might experience reduced response to subsequent immunotherapy.4